Key result
SGLT2 inhibitors and GLP-1 RAs improve cardiorenal outcomes in T2D, while DPP-4 inhibitors remain neutral.
Why the study?
Cardiovascular disease and chronic kidney disease are the leading causes of death in type 2 diabetes, and lowering glycated haemoglobin alone does not adequately address this risk.
Do newer antidiabetic agents (SGLT2i, GLP-1 RAs, tirzepatide, DPP-4 inhibitors, once-weekly basal insulins) improve glycaemic efficacy, cardiorenal outcomes, and safety in patients with type 2 diabetes and cardiorenal disease?
Do newer antidiabetic agents (SGLT2i, GLP-1 RAs, tirzepatide, DPP-4 inhibitors, once-weekly basal insulins) improve glycaemic efficacy, cardiorenal outcomes, and safety in patients with type 2 diabetes and cardiorenal disease?
SGLT2 inhibitors and GLP-1 receptor agonists provide distinct cardiorenal protection in patients with type 2 diabetes, underscoring the need to prioritize organ protection alongside glycaemic control, particularly in high-prevalence regions like the Middle East and North Africa.
Answers are grounded in this paper and cite their sources.
Reinforces cardiorenal benefits of SGLT2i and GLP-1 RAs in T2D; extends data to tirzepatide but leaves comparative efficacy open.
Cardiovascular disease and chronic kidney disease are the leading causes of death in type 2 diabetes, and lowering glycated haemoglobin alone does not adequately address this risk. This narrative review summarises evidence on the glycaemic efficacy, cardiorenal outcomes and safety of sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide, dipeptidyl peptidase-4 inhibitors and once-weekly basal insulins, with attention to the Gulf region. PubMed/MEDLINE, ScienceDirect and Google Scholar were searched for trials, meta-analyses and guidelines published between 2015 and 2026. SGLT2i provide the most consistent reductions in heart failure hospitalisation and kidney disease progression, irrespective of diabetes status. GLP-1 RAs reduce major adverse cardiovascular events, stroke and kidney outcomes. Tirzepatide offers the greatest glycaemic and weight benefits, with cardiovascular protection comparable to an established GLP-1 RA. Dipeptidyl peptidase-4 inhibitors and weekly insulins are largely cardiorenal-neutral. Combining SGLT2i and GLP-1 RAs may provide additive protection. In the Middle East and North Africa, which has the highest diabetes prevalence worldwide, use of these organ-protective agents remains low. Therapy should be selected according to comorbidity, giving organ protection the same priority as glycaemic control.
No takes yet. Share an insight, caveat, or question.
Sayed Mahmood Alqallaf (2026) conducted a review in Type 2 diabetes and cardiorenal disease. SGLT2 inhibitors, GLP-1 receptor agonists, tirzepatide, DPP-4 inhibitors, and once-weekly basal insulins was evaluated on Glycaemic efficacy, cardiorenal outcomes, and safety.
Synapse has enriched 10 related papers. Consider them for comparative context: